The expression of SMN1, MART3, GLE1 and FUS genes in spinal muscular atrophy
Abstract
Introduction. Spinal muscular atrophy (SMA) is one of the most common genetic causes of death in infants due to a mutation of the motor neuron 1 (SMN1) gene. The SMN1 gene encodes for the multifunctional SMN protein. SMN has been shown to be implicated in pre-mRNA splicing, mRNA transport and translational control. Also other mRNA processing proteins, such as GLE1, Marten (MART3) and Fused in Sarcoma (FUS), have been linked to neurodegenerative diseases. The aim of the study was to determine the expression of SMN, GLE1, MART3 and FUS genes in cell lines of the fibroblasts derived from SMA patients and normal controls.
Material and methods. Total RNA was extracted from purchased fibroblasts acquired from three SMA type I patients and fibroblasts of three age-matched healthy controls. The RNA was then subjected to qPCR analysis using primers specific for the GLE1, MART3, FUS and SMN1 genes vs. GAPDH as internal control gene.
Results. SMN1 mRNA levels were at least ×10 lower in fibroblasts of SMA patients compared to controls. Gle1 and MART3 gene expression was ×2 downregulated whereas FUS mRNA levels appeared to be ×3 upregulated in SMA cells when compared to controls. We found a high correlation between FUS gene expression level to the SMN1 at gene expression level of fibroblast cell lines of SMA type I patients (r = 0.994, p < 0.0001).
Conclusions. Our preliminary data show an intriguing expression profile of Gle1, MART3 and FUS genes in SMA, and suggest a critical role of FUS protein in the SMA pathogenesis.
Keywords: Spinal muscular atrophyfibroblastsGLE1SMN1FUSMART3qPCR
References
- Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013; 19(1): 40–50.
- Liu H, Shafey D, Moores JN, et al. Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy. J Neurosci Res. 2010; 88(1): 111–122.
- Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002; 111(6): 477–500.
- Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80(1): 155–165.
- Liscic RM, Grinberg LT, Zidar J, et al. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol. 2008; 15(8): 772–780.
- Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010; 466(7310): 1069–1075.
- Boehringer A, Garcia-Mansfield K, Singh G, et al. ALS Associated Mutations in Matrin 3 Alter Protein-Protein Interactions and Impede mRNA Nuclear Export. Sci Rep. 2017; 7(1): 14529.
- Guerreiro R, Brás J, Hardy J. SnapShot: Genetics of ALS and FTD. Cell. 2015; 160(4): 798–798.e1.
- Johnson JO, Pioro EP, Boehringer A, et al. ITALSGEN. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014; 17(5): 664–666.
- Liu EY, Cali CP, Lee EB. RNA metabolism in neurodegenerative disease. Dis Model Mech. 2017; 10(5): 509–518.
- Bäumer D, Hilton D, Paine SML, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010; 75(7): 611–618.
- Murphy R, Wente SR. An RNA-export mediator with an essential nuclear export signal. Nature. 1996; 383(6598): 357–360.
- Mirra A, Rossi S, Scaricamazza S, et al. Publisher Correction: Functional interaction between FUS and SMN underlies SMA-like splicing changes in wild-type hFUS mice. Sci Rep. 2018; 8(1): 7005.
- Belgrader, P., R. Dey, and R. Berezney, Molecular cloning of matrin 3. A 125-kilodalton protein of the nuclear matrix contains an extensive acidic domain. J Biol Chem, 1991. 266(15): p. : 9893–9.
- Salton M, Elkon R, Borodina T, et al. Matrin 3 binds and stabilizes mRNA. PLoS One. 2011; 6(8): e23882.
- Seytanoglu A, Alsomali NI, Valori CF, et al. Deficiency in the mRNA export mediator Gle1 impairs Schwann cell development in the zebrafish embryo. Neuroscience. 2016; 322: 287–297.
- Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010; 28(3): 271–274.
- Lukashchuk V, Lewis KE, Coldicott I, et al. AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice. Mol Ther Methods Clin Dev. 2016; 3: 15055.
- Schwartz JC, Ebmeier CC, Podell ER, et al. FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes & Development. 2012; 26(24): 2690–2695.
- Yu Y, Reed R. FUS functions in coupling transcription to splicing by mediating an interaction between RNAP II and U1 snRNP. Proc Natl Acad Sci U S A. 2015; 112(28): 8608–8613.
- Yamaguchi A, Takanashi K. FUS interacts with nuclear matrix-associated protein SAFB1 as well as Matrin3 to regulate splicing and ligand-mediated transcription. Sci Rep. 2016; 6: 35195.
- Bolger TA, Folkmann AW, Tran EJ, et al. The mRNA export factor Gle1 and inositol hexakisphosphate regulate distinct stages of translation. Cell. 2008; 134(4): 624–633.
- Zeng Y, Wang G, Yang E, et al. Aberrant gene expression in humans. PLoS Genet. 2015; 11(1): e1004942.
- Sun S, Ling SC, Qiu J, et al. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat Commun. 2015; 6: 6171.
- Mirra A, Rossi S, Scaricamazza S, et al. Functional interaction between FUS and SMN underlies SMA-like splicing changes in wild-type hFUS mice. Sci Rep. 2017; 7(1): 2033.
- Gama-Carvalho M, L Garcia-Vaquero M, R Pinto F, et al. Linking amyotrophic lateral sclerosis and spinal muscular atrophy through RNA-transcriptome homeostasis: a genomics perspective. J Neurochem. 2017; 141(1): 12–30.
